← Back to Clinical Trials
Recruiting Phase 4 NCT06683833

NCT06683833 Comparison Between Egyptian MTA, Biodentine Versus Calcium Hydroxide as Indirect Pulp Capping Materials In Permanent Teeth

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06683833
Status Recruiting
Phase Phase 4
Sponsor Cairo University
Condition Deep Caries
Study Type INTERVENTIONAL
Enrollment 35 participants
Start Date 2025-09-03
Primary Completion 2026-05-03

Eligibility & Interventions

Sex All sexes
Min Age 22 Years
Max Age 45 Years
Study Type INTERVENTIONAL
Interventions
Egyptian MTABiodentineCalcium Hydroxide (Ca(OH)2)

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

Phase 4 studies follow an already-approved treatment in real-world conditions to monitor long-term safety and effectiveness.

This trial targets 35 participants in total. It began in 2025-09-03 with a primary completion date of 2026-05-03.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Compare the clinical performance and patient satisfaction of Egyptian MTA, Biodentine versus Calcium Hydroxide as indirect pulp capping materials in permanent teeth

Eligibility Criteria

Inclusion Criteria: * Adult patients aged 22: 45 years old. * Males or females. * Patients with vital teeth with deep carious lesions. * Patients in good general health. * Good oral hygiene. * Co-operative patients who show interest to participate in the study. Exclusion Criteria: * Patients with systemic diseases. * Patients with known allergic or adverse reaction to the tested materials. * Patients with bad oral hygiene. * Patient who frequently use analgesic or any drugs that could mask the pain.

Contact & Investigator

Central Contact

Alaa T Elsorogy, Master's candidate

✉ alaa.elsorogy@dentistry.cu.edu.eg

📞 0020201010009938

Frequently Asked Questions

Who can join the NCT06683833 clinical trial?

This trial is open to participants of all sexes, aged 22 Years or older, up to 45 Years, studying Deep Caries. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

What phase is the NCT06683833 trial and what does that mean for participants?

Phase 4 studies are conducted after a treatment has been approved. They monitor long-term safety and real-world effectiveness in a broader patient population.

Is NCT06683833 currently recruiting?

Yes, NCT06683833 is actively recruiting participants. Contact the research team at alaa.elsorogy@dentistry.cu.edu.eg for enrollment information.

Where is the NCT06683833 trial being conducted?

This trial is being conducted at Cairo, Egypt.

Who is sponsoring the NCT06683833 clinical trial?

NCT06683833 is sponsored by Cairo University. The trial plans to enroll 35 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology